Sirona Biochem (TSX-V: SBM) presents a specialized biotech play focused on carbohydrate chemistry, a field they claim has immense commercial potential based on historical blockbusters like Tamiflu and Lovenox. Operating through their French subsidiary TFChem, the company utilizes a licensing-heavy business model designed to generate up-front fees, milestones, and royalties without the capital intensity of full-scale drug manufacturing. The deck emphasizes the 2021 commercial launch of their skin-lightening compound TFC-1067 with partner Rodan + Fields and ongoing preclinical work in anti-wrin…
Key takeaways
- The company operates as a cosmetic ingredient and drug discovery firm using a proprietary platform to stabilize carbohydrate molecules (Slide 2).
- Sirona Biochem is publicly traded on the TSX-V under the symbol SBM, with a market cap of $52,553,000 as of March 3, 2022 (Slide 2).
- The business model relies on licensing or selling patented compounds to global companies for up-front fees, milestones, and royalties (Slide 4).
- A major commercial milestone was achieved in 2021 with the launch of a product containing TFC-1067 by licensing partner Rodan + Fields (Slide 2).
- Clinical data for TFC-1067 claims superiority over the 'gold standard' hydroquinone for treating hyperpigmentation (Slide 5).
- The company is diversifying its pipeline with an anti-viral program launched in April 2020, testing 20 new compounds for COVID-19 (Slide 2).
- Management includes a CFO with 28 years of experience and a VP of Operations with 21 years in biotech, though a CEO profile is missing from the provided slides (Slide 7).
- The deck leverages the success of existing carbohydrate-based drugs like Tamiflu ($2.9B sales during H1N1) to validate the sector's potential (Slide 3).
Slide-by-Slide Analysis
Slide 1: Title Slide
The cover slide introduces Sirona Biochem with the tagline 'Advancing Chemistry. Enhancing Health.' It identifies the company's ticker symbol (TSX-V: SBM) and dates the presentation to March 2022. The imagery is standard laboratory-focused biotech branding, featuring glassware and a scientist in the background.
Slide 2: Investment Highlights and Fundamental Data
This slide serves as a summary of the company's value proposition and public market standing. It notes that the technology is based on 20 years of research by an 'award winning CSO' through a French subsidiary, TFChem. Key milestones mentioned include a manufacturing agreement in China and the 2021 launch of a product with Rodan + Fields. The 'Fundamental Data' table provides a snapshot of the stock's performance as of March 3, 2022, listing 250,251,526 shares outstanding and a market cap of $52,553,000. The share price is noted at $0.21, with a year high of $0.56 and a low of $0.14.
Slide 3: The Potential of Carbohydrate Compounds
Sirona uses this slide to validate the market category. They argue that carbohydrate compounds have 'immense commercial potential' by citing historical successes. Specifically, they point to Tamiflu (anti-viral) with sales exceeding $2.9 Billion USD during the H1N1 outbreak, and Lovenox (blood thinner) with $1.73 Billion USD in sales in 2018. This is a classic 'social proof' slide for a scientific niche, linking Sirona's focus to proven multi-billion dollar markets.
Slide 4: Business Model
The business model is described as a pure-play licensing strategy. Sirona develops and patents compounds, then licenses them to 'leading global companies.' The revenue streams are clearly defined: up-front fees, milestone fees, and ongoing royalty payments. This model is attractive to investors because it reduces the capital expenditure required for manufacturing and distribution, shifting those costs to the licensing partners.
Slide 5: TFC-1067 Clinical Study
This slide provides technical validation for their lead compound, TFC-1067. It details a 12-week double-blind study with 48 participants conducted by Dr. Zoe Draelos in the USA. The key claim is 'superiority to the gold standard, hydroquinone' for treating hyperpigmentation. The slide asserts that the compound achieved its endpoint of lightening skin without safety issues, providing 'strong evidence' for its use as a replacement for existing treatments.
Slide 6: About Us (Transition)
A simple transition slide titled 'About Us' with the company logo and a dark, stylized background of lab equipment.
Slide 7: Management
The management slide profiles two key executives. Christopher Hopton, CFO, is highlighted for his 28 years of experience in financial management, including roles at Central Resources Corp. and Canadian Airlines. Michelle Seltenrich, VP of Operations, is credited with 21 years of experience in biotech, specifically in R&D lab management and M&A. Both profiles emphasize their education at Simon Fraser University and the University of British Columbia. Notably, a CEO or CSO profile is absent from this specific slide, which is an unusual omission for a management summary.
Slide 8: Contact Information
The final slide provides the company website and a general inquiry email address. It also reiterates the trading symbols for the TSX-V (SBM), Frankfurt (ZSB), and US-OTC (SRBCF) markets, set against an architectural background of a modern office building.
What Sirona Biochem Does Well
The deck is highly effective at articulating a clear, low-risk business model. By focusing on licensing rather than full-cycle production, Sirona positions itself as a high-margin intellectual property house. The use of Slide 3 to benchmark their technology against multi-billion dollar drugs like Tamiflu provides immediate context for the 'why now' and the scale of the opportunity. Furthermore, the inclusion of specific clinical trial parameters (Slide 5) adds a layer of scientific credibility that is often missing from early-stage biotech decks. The 'Fundamental Data' section on Slide 2 is also a transparent way to handle the realities of being a micro-cap public company, providing investors with the necessary liquidity and valuation metrics upfront.
What is Missing from the Deck
The most glaring omission in the provided slides is the absence of a CEO or Chief Scientific Officer (CSO) in the management section. While Slide 2 mentions an 'award winning CSO,' the management slide (Slide 7) only lists the CFO and VP of Operations. In biotech, the scientific pedigree of the lead researcher is often the primary driver of investor confidence. Additionally, there is no 'Ask' slide. While this is common for general investor relations decks for public companies, a fundraising deck usually specifies how much capital is being sought and exactly how it will be deployed (e.g., '50% to Phase II trials, 30% to IP filing'). Finally, there is no detailed competitive landscape. While they mention being better than the 'gold standard' hydroquinone, they do not address other emerging biotech competitors in the carbohydrate stabilization space.
Instructions for Founders
Founders in the deep-tech or biotech space should look at Slide 4 as a template for explaining a licensing model. It is concise and uses industry-standard terminology (up-front, milestones, royalties) that investors understand. The 'Investment Highlights' on Slide 2 is also a strong example of how to mix technical achievements with commercial milestones; notice how they lead with 'Proprietary technology' but immediately follow with 'Signed commercial-scale manufacturing agreement.' This balances scientific promise with business execution. However, founders should avoid the mistake of omitting the lead scientist from the team slide. In any technical venture, the person holding the 'secret sauce' must be front and center to validate the technical risk.
Frequently asked questions
- What is Sirona Biochem's primary technology focus?
- Sirona Biochem focuses on a proprietary platform technology developed by their French subsidiary, TFChem. This technology specializes in stabilizing carbohydrate molecules. The goal is to improve the efficacy and safety of these molecules for use as active ingredients in both the cosmetic and pharmaceutical industries.
- How does the company generate revenue?
- The company follows a licensing-based business model. Instead of manufacturing and marketing end-user products themselves, they develop and patent active ingredients. They then license or sell these patented compounds to large global companies in exchange for up-front fees, milestone payments, and ongoing royalties.
- What is the significance of the TFC-1067 compound?
- TFC-1067 is the company's lead commercial product, a skin-lightening ingredient. According to the deck, a 12-week double-blind clinical study showed it was superior to hydroquinone, the previous 'gold standard,' for treating dark spots. It was commercially launched in 2021 through a partnership with Rodan + Fields.
- Is Sirona Biochem a private startup or a public company?
- Sirona Biochem is a publicly traded company. As of the March 2022 presentation, it was listed on the TSX Venture Exchange (TSX-V: SBM), the Frankfurt Stock Exchange (ZSB), and the US OTC market (SRBCF). Its market cap at the time was stated as $52,553,000 CAD.
- What new programs are in the company's development pipeline?
- Beyond skin lightening, the company is developing anti-wrinkle therapies with plans for 2022 clinical trials. They also launched an anti-viral program in 2020 with 20 compounds being tested for COVID-19 in the USA, and they have pending patents for novel anti-cellulite compounds.
